Squarepoint’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-105,180
| Closed | -$5.78M | – | 4375 |
|
|
2025
Q3 | $5.78M | Buy |
105,180
+86,782
| +472% | +$3.58M | 0.01% | 1373 |
|
|
2025
Q2 | $608K | Sell |
18,398
-85,480
| -82% | -$2.97M | ﹤0.01% | 3105 |
|
|
2025
Q1 | $4.17M | Buy |
103,878
+84,039
| +424% | +$3.86M | 0.01% | 1541 |
|
|
2024
Q4 | $933K | Sell |
19,839
-85,968
| -81% | -$4.46M | ﹤0.01% | 3132 |
|
|
2024
Q3 | $5.59M | Buy |
+105,807
| New | +$5.9M | 0.01% | 1347 |
|
|
2024
Q2 | – | Sell |
-25,700
| Closed | -$1.55M | – | 4167 |
|
|
2024
Q1 | $1.8M | Buy |
+25,700
| New | +$1.99M | ﹤0.01% | 2154 |
|
|
2023
Q1 | – | Sell |
-16,398
| Closed | -$751K | – | 3334 |
|
|
2022
Q4 | $751K | Buy |
+16,398
| New | +$706K | ﹤0.01% | 2031 |
|
|
2022
Q2 | – | Sell |
-114,537
| Closed | -$4.22M | – | 2963 |
|
|
2022
Q1 | $4.22M | Buy |
114,537
+94,766
| +479% | +$3.37M | 0.02% | 797 |
|
|
2021
Q4 | $901K | Sell |
19,771
-71,644
| -78% | -$2.76M | ﹤0.01% | 1760 |
|
|
2021
Q3 | $3.27M | Sell |
91,415
-76,333
| -46% | -$2.25M | 0.01% | 973 |
|
|
2021
Q2 | $3.32M | Buy |
167,748
+145,974
| +670% | +$3.43M | 0.01% | 918 |
|
|
2021
Q1 | $506K | Sell |
21,774
-53,470
| -71% | -$1.14M | ﹤0.01% | 2008 |
|
|
2020
Q4 | $1.56M | Buy |
75,244
+17,496
| +30% | +$320K | 0.01% | 1063 |
|
|
2020
Q3 | $1.25M | Buy |
57,748
+36,860
| +176% | +$862K | 0.02% | 873 |
|
|
2020
Q2 | $492K | Buy |
+20,888
| New | +$392K | 0.01% | 1328 |
|
|
2020
Q1 | – | Sell |
-54,732
| Closed | -$581K | – | 1995 |
|
|
2019
Q4 | $581K | Sell |
54,732
-62,799
| -53% | -$645K | ﹤0.01% | 1677 |
|
|
2019
Q3 | $1.34M | Buy |
117,531
+58,327
| +99% | +$732K | 0.01% | 1032 |
|
|
2019
Q2 | $666K | Buy |
59,204
+29,135
| +97% | +$281K | 0.01% | 1499 |
|
|
2019
Q1 | $243K | Buy |
30,069
+18,469
| +159% | +$136K | ﹤0.01% | 1867 |
|
|
2018
Q4 | $73K | Buy |
11,600
+1,438
| +14% | +$10.5K | ﹤0.01% | 1826 |
|
|
2018
Q3 | $100K | Buy |
+10,162
| New | +$81.5K | ﹤0.01% | 1884 |
|
|
2018
Q1 | – | Sell |
-139,925
| Closed | -$1.14M | – | 1769 |
|
|
2017
Q4 | $1.14M | Buy |
139,925
+68,754
| +97% | +$781K | 0.02% | 772 |
|
|
2017
Q3 | $1.03M | Sell |
71,171
-9,801
| -12% | -$134K | 0.02% | 714 |
|
|
2017
Q2 | $980K | Buy |
80,972
+66,312
| +452% | +$922K | 0.02% | 734 |
|
|
2017
Q1 | $188K | Buy |
14,660
+4,390
| +43% | +$51.3K | 0.01% | 1301 |
|
|
2016
Q4 | $125K | Buy |
+10,270
| New | +$109K | 0.01% | 1585 |
|
|
2016
Q2 | – | Sell |
-13,200
| Closed | -$93K | – | 1148 |
|
|
2016
Q1 | $93K | Buy |
+13,200
| New | +$96.4K | 0.01% | 1075 |
|
Other funds holding CYTK
DTC
RI
Squarepoint's CYTK Position: Q4 2025 in Review
Squarepoint sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 105,180 shares — an estimated $5.78M sold.
Squarepoint first reported a position in CYTK in Q1 2016 and held it in 27 quarters. The position peaked at $5.78M in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.
- Squarepoint reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
- Squarepoint sold 105,180 Cytokinetics shares in Q4 2025, an estimated $5.78M.
- Squarepoint first reported a position in Cytokinetics in Q1 2016 and held it in 27 quarters.
- Squarepoint's Cytokinetics position peaked at $5.78M in Q3 2025.
- 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.
Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.